- Home
- DMO vs AVTX Comparison
DMO vs AVTX Comparison
Compare DMO & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMO
- AVTX
- Stock Information
- Founded
- DMO 2009
- AVTX 2011
- Country
- DMO United States
- AVTX United States
- Employees
- DMO N/A
- AVTX N/A
- Industry
- DMO Trusts Except Educational Religious and Charitable
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- DMO Finance
- AVTX Health Care
- Exchange
- DMO Nasdaq
- AVTX Nasdaq
- Market Cap
- DMO 135.9M
- AVTX 138.8M
- IPO Year
- DMO N/A
- AVTX 2015
- Fundamental
- Price
- DMO $12.00
- AVTX $11.33
- Analyst Decision
- DMO
- AVTX Strong Buy
- Analyst Count
- DMO 0
- AVTX 9
- Target Price
- DMO N/A
- AVTX $30.14
- AVG Volume (30 Days)
- DMO 49.6K
- AVTX 188.1K
- Earning Date
- DMO 01-01-0001
- AVTX 11-06-2025
- Dividend Yield
- DMO 12.06%
- AVTX N/A
- EPS Growth
- DMO N/A
- AVTX N/A
- EPS
- DMO N/A
- AVTX N/A
- Revenue
- DMO N/A
- AVTX $441,000.00
- Revenue This Year
- DMO N/A
- AVTX N/A
- Revenue Next Year
- DMO N/A
- AVTX N/A
- P/E Ratio
- DMO N/A
- AVTX N/A
- Revenue Growth
- DMO N/A
- AVTX N/A
- 52 Week Low
- DMO $10.00
- AVTX $3.39
- 52 Week High
- DMO $11.80
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- DMO 61.82
- AVTX 62.61
- Support Level
- DMO $11.89
- AVTX $9.54
- Resistance Level
- DMO $11.98
- AVTX $12.41
- Average True Range (ATR)
- DMO 0.06
- AVTX 1.05
- MACD
- DMO 0.01
- AVTX -0.10
- Stochastic Oscillator
- DMO 97.37
- AVTX 71.28
About DMO Western Asset Mortgage Opportunity Fund Inc.
Western Asset Mortgage Defined Opportunity Fund Inc is a non-diversified, limited-term, closed-end management investment company. The fund's primary investment objective is to provide current income. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing in a diverse portfolio of mortgage-backed securities, consisting of non-agency residential mortgage-backed securities and commercial mortgage-backed securities.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).